Mcs Med

Based in Shaoxing, China and founded in 2024, Maikesi Medical Technology (Shaoxing) Co. , Ltd. , doing business as Mcs Med, operates as a medical company that focuses on the research and development of pan-vascular emergency care and cardiac circulatory support devices. In July 2024, Mcs Med closed angel funding from new investor Puhua Capital.

In December 2025, closed pre-series A funding led by new investor National Innovation Center for High Performance Medical Devices, with participation from new investor Originvest Capital. Mcs Med is mainly engaged in the research and development of pan-vascular emergency care and cardiac circulatory support devices with core products such as the PulseVAD® interventional ventricular assist system and the Mcsreboa® resuscitation aortic occlusion balloon. PulseVAD® is an ultra-thin catheter-based artificial heart with a catheter diameter of less than 14 Fr featuring an external pump and key internal valves, enables operation in sync with the heart rhythm, achieving efficient pulsatile blood flow support. Mcsreboa® integrates ultrasound, automatic inflation, and a guidewire-free design allowing emergency medical personnel to locate the occlusion position and automatically inflate the balloon to achieve hemostasis.

The company generates revenue by providing medical devices. The pre-series A funding will be used by the company to accelerate the R&D and clinical trials of core products, promote product registration and certification, complete production line construction and upgrades, and further consolidate its leading position in the domestic market for vascular and cardiac life support systems.